Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 2Leukemia, Monocytic, Acute 2Thrombocythemia, Essential 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 9Mycophenolic Acid 9Cyclophosphamide 8Busulfan 8Tacrolimus 7Cyclosporine 5ruxolitinib 4fludarabine 4Methotrexate 4Antilymphocyte Serum 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2Stem Cell Transplantation 2Radiotherapy 2Melphalan 2Etoposide 2Carboplatin 2veliparib 1thymoglobulin 1sonidegib 1pomalidomide 1merphos 1bomedemstat 1anagrelide 1Transplantation 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thrombocythemia, Essential × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡